Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, Phase I dose-escalation study of the combination of
AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST. This study is designed
to determine the Phase II dose of AMN107 and imatinib when administered together in patients
with imatinib-resistant GIST, and to characterize the safety, tolerability and
pharmacokinetic (PK) profile of this combination.